These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35546110)

  • 1. Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Diamond TL; Ngo W; Xu M; Goh SL; Rodriguez S; Lai MT; Asante-Appiah E; Grobler JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013322. PubMed ID: 35546110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Lai MT; Feng M; Xu M; Ngo W; Diamond TL; Hwang C; Grobler JA; Hazuda DJ; Asante-Appiah E
    Antimicrob Agents Chemother; 2022 May; 66(5):e0222321. PubMed ID: 35491829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
    Cilento ME; Reeve AB; Michailidis E; Ilina TV; Nagy E; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116721. PubMed ID: 34516245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
    White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
    Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
    Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
    J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
    Andreatta KN; Goodman DD; Miller MD; White KL
    Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
    Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.
    Álvarez M; Sebastián-Martín A; García-Marquina G; Menéndez-Arias L
    Sci Rep; 2017 Mar; 7():44834. PubMed ID: 28333133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
    Hu Z; Kuritzkes DR
    J Virol; 2011 Nov; 85(21):11309-14. PubMed ID: 21849432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
    Gregson J; Rhee SY; Datir R; Pillay D; Perno CF; Derache A; Shafer RS; Gupta RK
    J Infect Dis; 2020 Sep; 222(7):1108-1116. PubMed ID: 31774913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
    Andreatta KN; Miller MD; White KL
    Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
    J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
    Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.